Cirdan and Targos strengthen their commitment to supporting pathologist professional development
Cirdan, a global leader in pathology informatics and imaging, and Targos, a global leader in clinical biomarker services today announced that they have consolidated their commitment to advancing digital pathology education and the professional development of pathologists in a new collaboration agreement.
Targos has been successfully using PathXL Tutor, Cirdan’s digital pathology course and assessment creation platform to train and assess more than 1000 pathologists globally since 2018. The PathXL Tutor software has enabled Targos to transform its traditional glass microscopy courses for HER2 and PD-L1 evaluation into a high-quality digital learning experience.
Following the acquisition of Belfast-based Philips Digital and Computational Pathology business (formerly known as PathXL) in July 2020, Cirdan has enhanced its existing product offering with PathXL’s digital pathology, image analysis, deep learning and educational tools. As part of this, Cirdan has invested further in refining and developing the successful PathXL Tutor software platform and will continue to work with Targos to support the professional development of pathologists and help them to provide a sustainable approach for international biomarker standardization.
Commenting on the collaboration Prof. Dr. Josef Rüschoff, CMO at Targos, said:
We are delighted to see that PathXL and Cirdan have combined their resources, bringing the best of each to the market. The platform is an invaluable tool for our Targos Advance expert biomarker training and assessment courses for pathologists. It enables a global offering of the highest-level virtual slide education. We very much look forward to further developing the platform in our partnership with Cirdan and to the benefits this will bring.
Dr. Hugh Cormican, CEO at Cirdan added:
We believe strongly in providing pathologists with the technology they need to be able to do their jobs more efficiently and effectively. Education and professional development play a big part in this and we are pleased to work with Targos in the continued promotion of PathXL Tutor to pathologists across the globe.
PathXL Tutor is currently being used by a wide range of public and private institutions across the world, including universities, professional societies and hospitals with residency programs, amongst others. This collaboration announcement comes as Cirdan gets ready to release the latest version of PathXL Tutor.
Cirdan is a leading provider of medical informatics and imaging technology that is primarily used in pathology to enhance and accelerate diagnosis. Headquartered in Northern Ireland, with offices in Canada and Australia, Cirdan’s systems are currently helping to increase efficiency and streamline operations in public and private healthcare organisations across six continents. Following Cirdan’s merger with PathXL in July 2020 Cirdan has enhanced its digital pathology and artificial intelligence capabilities, further strengthening its position as a leader in the global pathology market.
Targos’s core service business is to provide highly standardized development and application of clinical biomarkers for the international pharmaceutical and diagnostic industry. The company has supported more than 700 international clinical trials since 1999, which have led to the approval of several targeted therapies and IVDs for our customers. The expert team of on-site clinical pathologists operates in a professional environment of project management, logistics, data and quality management. Targos also supports the introduction of new Companion Diagnostic assays into the clinical routine by performing Targos Advance training courses for the international standardization of biomarkers. Targos is a fully GCP-compliant central laboratory that is inspected by the U.S. Food and Drug Administration (FDA). Targos Molecular Pathology GmbH is accredited by the College of American Pathologists (CAP) and the Clinical Laboratory Improvement Amendments (CLIA).